However, double positive tumors (HLA-G and HLA-E) could per se show additive effects of both immune-modulatory molecules to increase the chance of immune evasion indicating that both targets (HLA-G and HLA-E) should be discussed as potential targets for immune therapies in RCC patients (Supplementary Figure 2). This evidence concerns the gene HLA-E and renal cell carcinoma.